Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination.
about
Current concepts in thrombotic thrombocytopenic purpuraHematopoietic cell transplantation-associated thrombotic microangiopathy: a review of pathophysiology, diagnosis, and treatmentCalcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome.Thrombotic microangiopathy after kidney transplantation.Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting?The role of endothelial cell injury in thrombotic microangiopathy.Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation.Successful conversion to belatacept after thrombotic microangiopathy in kidney transplant patients.Use of belatacept as alternative immunosuppression in three renal transplant patients with de novo drug-induced thrombotic microangiopathyOccurrence of atypical HUS associated with influenza B.Hemolytic uremic syndrome after renal transplantationInterconnections between autophagy and the coagulation cascade in hepatocellular carcinoma.Multiple indications for everolimus after liver transplantation in current clinical practice.Thrombotic microangiopathy in haematopoietic cell transplantation: an update.NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: endocrine challenges-thyroid dysfunction, growth impairment, bone health, & reproductive risks.The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation.Drug-induced thrombosis--experimental, clinical, and mechanistic considerations.Predictors of avascular necrosis of bone in long-term survivors of hematopoietic cell transplantationThe Far Side of Vascular Injury: Nonconventional Vasoconstrictors, DNA-targeting Agents, and Agents Toxic to Vascular Smooth Muscle.Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy.Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys.Mycophenolate mofetil vs. sirolimus in kidney transplant recipients receiving tacrolimus-based immunosuppressive regimen.A case of atypical hemolytic uremic syndrome in a second renal transplant.Thrombotic microangiopathy following haematopoietic stem cell transplant.Use of belatacept to maintain adequate early immunosuppression in calcineurin-mediated microangiopathic hemolysis post-renal transplantPathology of Calcineurin and Mammalian Target of Rapamycin Inhibitors in Kidney TransplantationComplement-mediated renal diseases after kidney transplantation - current diagnostic and therapeutic options in and recurrent diseasesThrombotic microangiopathy after renal transplantation: Current insights in and recurrent disease
P2860
Q24656680-1ECE193E-E4D5-4A16-A029-FF94E9378A56Q28069228-8B8CE745-D4A4-4FC0-B68F-FD4379A1C4A3Q33369997-27D3AAB4-B8A5-4F2D-A2EF-6455577CE03AQ33372586-BDD9E2F0-AA17-414D-AF28-3A65D8A4E27CQ33375739-B3347A60-37F0-4055-81FD-F1D1A9D91805Q33391882-37767430-65FC-479C-8EAA-5A3733A6F7F6Q33393107-069D7930-AE27-4BA5-BC96-064B09B9B8C0Q33409586-C8945581-49DA-4452-8C8F-C9EE08FF3A7BQ33411321-4E619DA0-AE3F-4848-8BFD-E6A645073956Q33438621-51FE1DA0-9C3D-4D07-94BA-C04151A55960Q33598544-04282B98-D2D5-4BDD-B91C-AC6224DB5F0AQ33720303-2456E782-3EB4-4B8D-8E50-C43627DCAD27Q33891730-337EEC1E-394C-404D-BF32-A61F260431A7Q35098992-91598BE2-45CF-42B8-BAF3-BB9760F7DAFFQ35563274-60959FB6-7B6F-41B0-AFD4-3FC9124124CFQ36216192-7A335633-F89E-4806-94DB-4B0329D11A9EQ36762200-899D8720-B7F7-4779-B40A-B8DFCDD9C820Q37341385-8198C311-0A40-46E5-AA1A-59AA4BD79E6CQ38583684-97CC7A1E-E4A0-4972-9E9C-0CC41BEA19B3Q42364404-577E4AA0-486C-4804-BECC-C100BB4F4DDCQ46702750-06840A4E-3252-4E53-B1AF-314223708554Q46703423-A9E17ABB-E924-4740-A482-F593C798203EQ48209875-0C23864C-A5EF-47AF-AF91-74003C9D7E79Q49375853-EAE143D4-68AD-45B9-9B13-CC2C86A13D13Q56896789-4A1E57E2-C1EF-4ECF-8528-26BCC712CB6AQ57151742-6C93014F-F8B2-46FC-BD56-FE40A67E5B07Q58120548-10A3D1F4-9457-4AED-B82A-1F4D3F52B20BQ58754943-4C376CA4-A8EC-4ED8-8B06-7791C056C39E
P2860
Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Increased risk of thrombotic m ...... osporin-sirolimus combination.
@en
Increased risk of thrombotic m ...... osporin-sirolimus combination.
@nl
type
label
Increased risk of thrombotic m ...... osporin-sirolimus combination.
@en
Increased risk of thrombotic m ...... osporin-sirolimus combination.
@nl
prefLabel
Increased risk of thrombotic m ...... osporin-sirolimus combination.
@en
Increased risk of thrombotic m ...... osporin-sirolimus combination.
@nl
P2093
P2860
P1476
Increased risk of thrombotic m ...... osporin-sirolimus combination.
@en
P2093
François Madore
Gilles St-Louis
Jo-Ann Fugère
Marc-André Raymond
Marie-Chantal Fortin
Marie-Josée Hébert
Michel Pâquet
P2860
P304
P356
10.1111/J.1600-6143.2004.00428.X
P407
P577
2004-06-01T00:00:00Z